Prostaglandin and thromboxane synthesis enzymes and platelet aggregation pathway components

The Prostaglandin and thromboxane synthesis enzymes and platelet aggregation pathway components represent a critical biochemical network involved in hemostasis, vascular integrity, and inflammatory responses. Central to this system are the cyclooxygenase enzymes, COX-1 and COX-2, which convert arachidonic acid into prostaglandin H2, the common precursor for all prostanoids (UniProt P23219, P35354). In platelets, thromboxane synthase (TBXAS1) converts PGH2 into Thromboxane A2, a potent mediator that promotes platelet activation and vasoconstriction by binding to the thromboxane receptor (PubMed: 15123318). This pathway also interacts with other platelet aggregation components, such as the P2Y12 receptor and Glycoprotein IIb/IIIa, to ensure rapid clot formation at sites of vascular injury (StatPearls: Platelet Aggregation Inhibitors). Drugs targeting these components, including Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), are fundamental in treating pain, fever, and cardiovascular conditions like myocardial infarction (PubChem CID 2244). However, therapeutic modulation of this pathway carries significant safety concerns, particularly the risk of gastrointestinal bleeding and adverse renal effects due to the systemic inhibition of protective prostaglandins (NIH: LiverTox).

Other names

Arachidonic acid cascadeProstanoid biosynthetic pathwayCyclooxygenase pathwayPlatelet activation pathwayCOX-TXA2 pathway

Inhibition of cyclooxygenase (COX) enzymes to prevent prostaglandin and thromboxane synthesis; antagonism of P2Y12 or TP receptors; and inhibition of Glycoprotein IIb/IIIa receptors to prevent platelet cross-linking.